Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Date:11/19/2009

d by The Leukemia and Lymphoma Society of North America, and a Phase 1/2 randomized combination study with sorafenib in first-line hepatocellular carcinoma being conducted in Hong Kong.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera is completing a Phase 2A study of AEG33773 in diabetic neuropathic pain and is working to progress HGS1029 through early stage clinical development with its partner Human Genome Sciences (HGSI). Additional information on these programs can be found on Aegera's website at www.aegera.com.

SOURCE AEGERA THERAPEUTICS INC.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics welcomes two experienced executives to its board of directors
6. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
9. Fate Therapeutics Closes $30 Million Series B Financing
10. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
11. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... WA (PRWEB) May 21, 2013 Through ... trainings, and funds for lab equipment, 25 organizations will ... and importance of optics and photonics in daily life ... . , The organizations, located in 10 countries, are ... to be awarded by SPIE, the international society ...
(Date:5/21/2013)... The congress of the ERA-EDTA ... the biggest congress in Europe ... are in Istanbul to share ... pioneering studies have been presented: / (1) ... VIA HEMODIALYSATE REDUCES ESA USE" By SFP-iron ...
(Date:5/21/2013)... May 21, 2013 Smarter Security, Inc., ... solutions, today announced that Genzyme, a Sanofi company and ... Door Detective® CL for a multi-use facility in the ... four other Genzyme buildings, this latest order underscores the ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... FL (PRWEB) May 21, 2013 Many ... breakouts as contributor to acne. Recently physicians from ... of mental stress on the skin, and suggested using ... help reduce the chemicals produced from stress that cause ... from the negative feelings acne brings about, stress causes ...
Breaking Biology Technology:Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2
... Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the ... of pixantrone for the treatment of diffuse large B-cell ... Drug Administration,s (the "FDA") Division of Hematologic Products (the ... the PIX-R or PIX 306 trial, will compare a ...
... thigh bones that enable them to support huge loads whilst ... the journal Proceedings of the Royal Society B . ... of new materials based on thigh bone geometry. A ... collected thigh bone samples from British museum collections and zoos, ...
... , BOULDER, Colo.Physicists at the National,Institute of ... in which microwaves communicate with,a vibrating mechanical ... before in,similar experiments. The microscopic,apparatus is a ... control the,motion of a relatively large object ...
Cached Biology Technology:FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5Study of 90 animals' thigh bones reveals how they can efficiently carry loads 2Study of 90 animals' thigh bones reveals how they can efficiently carry loads 3NIST electromechanical circuit sets record beating microscopic 'drum' 2NIST electromechanical circuit sets record beating microscopic 'drum' 3
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... the world,s largest scientific society, invites news media ... September 8-12, 2013, in Indianapolis, Ind. It will ... at area hotels. , With more than 7,100 ... from astronomy to zoology ― the meeting ... rich assortment of spot news and feature possibilities. ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2
... a protein implicated in Alzheimer's disease, researchers at UT ... gene responsible for producing the specific protein ?called amyloid-beta ... and greatly reduce the protein's build-up in the brain. ... of Alzheimer's disease. , "The whole point of the ...
... researchers at Duke's Pratt School of Engineering have imaged ... demonstration showed that the probes could give surgeons a ... are performed through tiny "keyhole" incisions. , If the ... lead to more precise and safer endoscopic surgeries, said ...
... University of York have launched a new research project which ... Researchers from the University's Department of Biology are heading the ... cells for use in the repair of bone defects and ... in the UK and across Europe, as well as academics ...
Cached Biology News:DNA gene vaccine protects against harmful protein of Alzheimer's disease 2Rare Tibetan antelope listed as endangered 2Rare Tibetan antelope listed as endangered 3Bones from blood: Scientists aim to break new ground on fractures 2
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: